TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19187076

Group type: EXPERIMENTAL
Intervention: AVE5026 (5, 10, 20, 40, or 60 mg)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: AVE5026 (60 mg)
Number of subjects: 690
Study: 17265130

Group type: EXPERIMENTAL
Intervention: PATHS curriculum (intervention group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 15168134

Group type: EXPERIMENTAL
Intervention: Transprosthetic drainage system (TDS) used in 12 stems (TRIOS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Third-generation cementation technique used in 10 stems (CPS)
Number of subjects: 22
Study: 10735838

Group type: EXPERIMENTAL
Intervention: Ametop gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 120
Study: 8753732

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser prostatectomy alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KTP/532 laser therapy after Nd:YAG treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall group of 32 patients
Number of subjects: 32
Study: 1557967

Group type: EXPERIMENTAL
Intervention: fucithalmic drops twice daily
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: chloramphenicol (chlormycetin) ointment twice daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 104
Study: 3924879

Group type: EXPERIMENTAL
Intervention: Cefpiramide (HR-810)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin-sensitive isolates of Ps. aeruginosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin-resistant isolates of Ps. aeruginosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglycoside-resistance
Number of subjects: 0
Study: 30218626

Group type: EXPERIMENTAL
Intervention: rasagiline 0.5 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rasagiline 1.0 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rasagiline 2.0 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rasagiline 0.5 mg (multiple administration)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rasagiline 1.0 mg (multiple administration)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rasagiline 2.0 mg (multiple administration)
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 28419317

Group type: EXPERIMENTAL
Intervention: High-Frequency Lanreotide Autogel (120 mg/21 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-Dose Lanreotide Autogel (180 mg/28 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both HF and HD Lanreotide Autogel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 26510186

Group type: EXPERIMENTAL
Intervention: Low glucose degradation product (GDP) solution
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional solutions
Number of subjects: 68
Study: 23413042

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 21591985

Group type: EXPERIMENTAL
Intervention: NUTRIOSE(®) supplementation (17 g twice daily for 12 weeks)
Number of subjects: 60
Study: 19238652

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moxifloxacin concentration increase
Number of subjects: 20
Study: 17075115

Group type: EXPERIMENTAL
Intervention: Surgery followed by 6 months of systemic adjuvant chemotherapy with fluorouracil and folinic acid
Number of subjects: 173

Group type: COMPARATOR
Intervention: Surgery alone and observation
Number of subjects: 173
Study: 14534913

Group type: EXPERIMENTAL
Intervention: carbidopa/levodopa (25/100)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 10326742

Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg once daily for 5 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 80
Study: 8601548

Group type: EXPERIMENTAL
Intervention: Divalproex 20 mg/kg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Haloperidol 0.2 mg/kg/day
Number of subjects: 36
Study: 1752885

Group type: EXPERIMENTAL
Intervention: Early excision (within 72 hours of admission)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed excision (after 2 weeks post-injury)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 7125726

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 87

Group type: COMPARATOR
Intervention: Gastric partition
Number of subjects: 87
Study: 31674219

Group type: EXPERIMENTAL
Intervention: Side-by-side priming of self-efficacy items with behavioral intention items.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Definition priming of self-efficacy items with presentation of participant's definition of 'can'.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group completing the same questionnaire without priming.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Participants with strict definitions of 'can' in side-by-side priming.
Number of subjects: 134
Study: 31642066

Group type: EXPERIMENTAL
Intervention: Wellness Incentive and Navigation (WIN) intervention
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 1259
Study: 28605827

Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone plus a 30-day prescription
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 380 mg intramuscular naltrexone injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 54
Study: 25719534

Group type: EXPERIMENTAL
Intervention: Multimodal hand hygiene improvement intervention (electronic training video, hand sanitizer, educational posters)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study: 24311467

Group type: EXPERIMENTAL
Intervention: Weight loss alone (WL)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Weight loss with aerobic exercise (WL + AEX)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Weight loss (combined WL and WL + AEX)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Abdominal SAA secretion during WL
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gluteal SAA secretion
Number of subjects: 96
Study: 21895923

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (Group S)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (Group E)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous morphine followed by PCA (Group P)
Number of subjects: 75

Group type: COMPARATOR
Intervention: DO(2) I < 400 ml/min/m(2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: DO(2) I > 400 ml/min/m(2)
Number of subjects: 75
Study: 19255176

Group type: EXPERIMENTAL
Intervention: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus repeated infiltration of the same anesthetic 30 minutes later
Number of subjects: 40

Group type: COMPARATOR
Intervention: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus mock repeated infiltration 30 minutes later
Number of subjects: 40
Study: 17126039

Group type: EXPERIMENTAL
Intervention: Dopamine transporters measured using positron emission tomography and [11C]cocaine in ADHD subjects.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine transporters in putamen in ADHD subjects.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scores for inattention in ADHD subjects compared to controls.
Number of subjects: 20
Study: 16317972

Group type: EXPERIMENTAL
Intervention: Preventive dental care provided by nondental primary care providers
Number of subjects: 342
Study: 12172084

Group type: EXPERIMENTAL
Intervention: pVL rebounds
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: triple therapy
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: non-adherence
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: isolated pVL rebound
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: consecutive pVL rebounds
Number of subjects: 358
Study: 10384587

Group type: EXPERIMENTAL
Intervention: Evaluation methods in Clinical Informatics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10743848

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Presence of childhood psychiatric diagnosis
Number of subjects: 48
Study: 1884443

Group type: EXPERIMENTAL
Intervention: Digitalis (Cedilanid 0.02 ng/kg, n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dobutamine (2.8 ± 0.5 micrograms/kg/min, n = 8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 22
Study: 6615674

Group type: EXPERIMENTAL
Intervention: Thiopentone-nitrous oxide-enflurane anesthesia with controlled ventilation (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone-nitrous oxide-enflurane anesthesia with spontaneous ventilation (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regional analgesia (n = 10)
Number of subjects: 30
Study: 30625052

Group type: EXPERIMENTAL
Intervention: Hybrid minimally invasive esophagectomy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 207
Study: 30180291

Group type: EXPERIMENTAL
Intervention: Exercise only (G2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Exercise + Manipulation of expectations: No psychological effect (G3)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Exercise + Manipulation of expectations: Psychological effect (G4)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No Exercise (G1)
Number of subjects: 114
Study: 25311746

Group type: EXPERIMENTAL
Intervention: Open popliteal artery aneurysm repair (OPAR)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Endovascular popliteal artery aneurysm repair (EPAR)
Number of subjects: 148
Study: 23298885

Group type: EXPERIMENTAL
Intervention: Intravitreal VEGF Trap-Eye (VTE) 2 mg every 4 weeks for 24 weeks
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sham injections every 4 weeks for 24 weeks
Number of subjects: 177
Study: 21860988

Group type: EXPERIMENTAL
Intervention: NMES with medium-frequency current
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NMES with low-frequency current
Number of subjects: 20
Study: 18516012

Group type: EXPERIMENTAL
Intervention: Levofloxacin 300 mg, amoxicillin 1 g, and pantoprazole 20 mg, given twice daily for 7 days (LAP group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice, tetracycline 500 mg four times, pantoprazole 20 mg twice, bismuth subcitrate 600 mg twice daily for 7 days (MTPB group)
Number of subjects: 76
Study: 16870008

Group type: EXPERIMENTAL
Intervention: Fish oil/5‐MTHF treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12771974

Group type: EXPERIMENTAL
Intervention: Chitosan (1.2 g per day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10669844

Group type: EXPERIMENTAL
Intervention: Full mite allergen avoidance measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal regimen)
Number of subjects: 0
Study: 8842951

Group type: EXPERIMENTAL
Intervention: Dorsally placed sutures
Number of subjects: 26

Group type: COMPARATOR
Intervention: Palmarly placed sutures
Number of subjects: 26
Study: 1379963

Group type: EXPERIMENTAL
Intervention: Orgaran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 6437842

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg) with acarbose (3 X 100 mg daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glibenclamide (5 mg) with placebo
Number of subjects: 6
Study: 30796808

Group type: EXPERIMENTAL
Intervention: CNTs (ANAM, CogState, CNS Vital Signs, ImPACT)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 406
Study: 29331021

Group type: EXPERIMENTAL
Intervention: Partially microgrooved healing abutments
Number of subjects: 28

Group type: COMPARATOR
Intervention: Machined healing abutments
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 27405061

Group type: EXPERIMENTAL
Intervention: 200-mg group (50-mg intravenous bolus every 6 h during 7 days)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 300-mg group (100-mg initial bolus followed by continuous infusion of 300 mg daily for 5 days)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 200-mg group
Number of subjects: 122

Group type: COMPARATOR
Intervention: 300-mg group
Number of subjects: 122
Study: 24476555

Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer
Number of subjects: 128

Group type: COMPARATOR
Intervention: Online Psychoeducation (OPD)
Number of subjects: 128

Group type: COMPARATOR
Intervention: GET.ON Mood Enhancer and Online Psychoeducation
Number of subjects: 128
Study: 23225445

Group type: EXPERIMENTAL
Intervention: Menatetrenone (MNT) 45 mg daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-MNT group
Number of subjects: 101
Study: 20664964

Group type: EXPERIMENTAL
Intervention: ANXA10 expressing plasmid introduced into MKN-1 cells
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal surrounding mucosa
Number of subjects: 9
Study: 17420199

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 13778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13778
Study: 16301236

Group type: EXPERIMENTAL
Intervention: MgSO4 30 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 microg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12049574

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1636
Study: 9864884

Group type: EXPERIMENTAL
Intervention: Psychological support offered to the experimental group
Number of subjects: 632

Group type: COMPARATOR
Intervention: Usual therapeutic procedures followed in the control group
Number of subjects: 632
Study: 9164200

Group type: COMPARATOR
Intervention: Cyclophosphamide 500 mg/m2 plus fluorouracil 500 mg/m2 combined with mitoxantrone 10 mg/m2 (CNF)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 (CAF)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 249

Group type: COMPARATOR
Intervention: CNF
Number of subjects: 249
Study: 2719894

Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg daily for 13 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg daily for 13 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9110

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31213783

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 228

Group type: COMPARATOR
Intervention: Calcitonin/Placebo
Number of subjects: 228
Study: 28211816

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release oral levodopa-carbidopa (LC-oral) treatment
Number of subjects: 0
Study: 26408274

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 11186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11186
Study: 23237136

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d
Number of subjects: 27
Study: 21030194

Group type: EXPERIMENTAL
Intervention: Internet self-management problem solving program
Number of subjects: 41
Study: 19371823

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy within the first 30 days after index PCI
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy between 30 days and 6 months after index PCI
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy beyond 6 months after index PCI
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Undersizing of the coronary stent
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Presence of malignancy
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Intermediate coronary artery disease proximal to the culprit lesion
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction flow grade <3
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Dissection
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Lack of aspirin
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Bifurcation lesions
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Ejection fraction <30%
Number of subjects: 21009

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 21009
Study: 16684262

Group type: EXPERIMENTAL
Intervention: PPI/AM500
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI/AM750
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole)/AM500
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI (omeprazole)/AM500
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI (rabeprazole)/AM500
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI (lansoprazole)/AM750
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI (omeprazole)/AM750
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: PPI (rabeprazole)/AM750
Number of subjects: 228
Study: 15275944

Group type: EXPERIMENTAL
Intervention: Post-event processing (negative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-event processing (other types)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no post-event processing specified)
Number of subjects: 0
Study: 11521725

Group type: EXPERIMENTAL
Intervention: trastuzumab (single-agent)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: trastuzumab plus paclitaxel (weekly)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: trastuzumab plus docetaxel
Number of subjects: 206

Group type: COMPARATOR
Intervention: docetaxel ± trastuzumab
Number of subjects: 206

Group type: COMPARATOR
Intervention: aromatase inhibitor ± trastuzumab
Number of subjects: 206

Group type: COMPARATOR
Intervention: CMF ± trastuzumab
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: vinorelbine + trastuzumab
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: epirubicin-cyclophosphamide (EC) + trastuzumab
Number of subjects: 206

Group type: COMPARATOR
Intervention: epirubicin-cyclophosphamide (EC) alone
Number of subjects: 206
Study: 9220306

Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 7966805

Group type: EXPERIMENTAL
Intervention: Leg elevation (foot elevated 30 cm above heart level)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no leg elevation)
Number of subjects: 30
Study: 2957859

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nefo‐Dolpasse
Number of subjects: 67

Group type: COMPARATOR
Intervention: Other infusion solutions
Number of subjects: 67
Study: 29637407

Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring (EDM) for goal-directed fluid therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard fluid management (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring (EDM)
Number of subjects: 50
Study: 30634208

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC) 0.5 g/pill, 3 pills each time, 3 times per day for 90 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Leflunomide (LEF) Tablet 0.1 g/tablet, 1 tablet each time, once every evening for 90 days)
Number of subjects: 100
Study: 25330327

Group type: EXPERIMENTAL
Intervention: High protein-low carbohydrate (HPLC) diet (30/35/35% of energy from protein/carbohydrate/fat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High carbohydrate-low protein (HCLP) diet (5/60/35% of energy from protein/carbohydrate/fat)
Number of subjects: 16
Study: 22508307

Group type: EXPERIMENTAL
Intervention: 0.1% UC781 gel
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.25% UC781 gel
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: UC781 gel (both concentrations)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 25
Study: 20502386

Group type: EXPERIMENTAL
Intervention: Ketamine/midazolam (K/M)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Etomidate/fentanyl (E/F)
Number of subjects: 23
Study: 17904561

Group type: EXPERIMENTAL
Intervention: Modified technique (Joel-Cohen-Stark)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard technique (Pfannenstiel-Kerr)
Number of subjects: 600
Study: 16253582

Group type: EXPERIMENTAL
Intervention: Mild bleeding
Number of subjects: 26452

Group type: EXPERIMENTAL
Intervention: Moderate bleeding
Number of subjects: 26452

Group type: EXPERIMENTAL
Intervention: Severe bleeding
Number of subjects: 26452
Study: 12447162

Group type: EXPERIMENTAL
Intervention: Carvedilol initiated before hospital discharge
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care (Heart Failure Society of America guidelines)
Number of subjects: 375
Study: 10363611

Group type: EXPERIMENTAL
Intervention: Prednisolone (2 x 250 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aprotinin (6 Mio. KIU)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits ('Bioline' by Jostra)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No special measures (control group)
Number of subjects: 40
Study: 7669486

Group type: EXPERIMENTAL
Intervention: Remoxipride 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Thyrotropin release hormone (TRH)
Number of subjects: 8
Study: 2104091

Group type: EXPERIMENTAL
Intervention: 15 mg nicardipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0